Lecture 20/21 Flashcards
Prodrugs
1
Q
What makes a good drug?
A
- Good activity and selectivity on the right target
- ADMET
- Absorption (bioavailability), Distribution (plasma concentrations), Metabolism (inactive and active metabolites), Excretion (termination of drug action), and Toxicity (drug itself or its metabolites)
2
Q
Problems with ADMET (5)
A
- Incomplete absorption
- Too rapid or slow of transportation of drug into body
- Incomplete systemic delivery of agent
- Toxicity problems
- Poor site specificity
3
Q
Reasons for Prodrugs
A
- Bioavailability of many molecules is low due poor absorption or first pass metabolism
- Sometimes formulations can offset these drawbacks, but usually need a chemical solution like a prodrug to deal with the issues with ADMET
4
Q
Prodrugs
A
- Inactive compounds that are converted to active compounds in the body
- 15% of the Top 100 Drugs
- Biotransformation must occur before pharmacologic effect can take place
- Bypasses paradox of lipophilic enough to pass membranes and water soluble enough to enter solution, be bioavailable, and transport through body
- Transform from a lipophilic, non-polar molecule to a water soluble more polar molecule usually
5
Q
Prodrug Uses (6)
A
- Improving membrane permeability
- Prolonging activity
- Masking Toxicity and side effects
- Varying water solubility
- Drug targetting
- Improving chemical stability
6
Q
Promoiety
A
- Inactive prodrug component that is lipophilic and non-polar
- Drug + promoiety are covalently linked
- Ideal is that the promoiety alone is non-toxic and that the parent drug is released in high recovery ratios
7
Q
Prodrug Pharmaceutical Objectives (4)
A
- Increase solubility
- Increase chemical stability
- Improved taste and odor
- Decreased irritation and pain
8
Q
Prodrug PK Objectives (4)
A
- Increase absorption
- Decrease presystemic metabolism
- Increased absorption by non-oral routes
- Improved prolonged duration of action
9
Q
Prodrug PD Objectives (2)
A
- Masking of reactive agent to improve TI
2. In site activation of a cytotoxic agent
10
Q
Are the prodrug objectives intertwined?
A
Yes
11
Q
Prodrug Classifications
A
- Carrier-Linked
2. Bioprecursors
12
Q
Carrier-Linked Prodrug Classifications
A
- Bipartite Prodrugs
- Tripartite Prodrugs
- Mutual Prodrugs
13
Q
Carrier-Linked Prodrugs
A
- Contain temporary linkages between active substrate and a carrier group that improves physicochemical or PK properties
- Carrier group is easily removed in vivo (usually via hydrolysis)
- Carrier group must be non-toxic and biologically inactive when detached
14
Q
Bioprecursor
A
-Compound that is metabolized by molecule modification into new compound that may also be active or further metabolized into an active metabolite
15
Q
Carrier-Linked Advantages
A
- Increase absorption
- Injection site pain relief
- Elimination of unpleasant taste
- Decreased toxicity
- Decreased metabolic activation
- Increased chemical stability
- Prolonged or shortened action
16
Q
Carrier-Linked Prodrug Design Goals
A
- Link between drug and promoiety usually done via a covalent bond
- Prodrug is inactive or less active than the parent molecule
- Link between drug and moiety broken in vivo
- Prodrug and in vivo promoiety must be non-toxic
- Generation of active form must be rapid to ensure drug levels are effective at site of action and to minimize alternative prodrug metabolism or inactivation